Gerald Youker, MD
Endocrinology, Diabetes & Metabolism · Portland, ORNPI 1912908138
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,492 and has fallen 70.1% since, to $446 in 2025.
Across 260 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$637
- Lilly USA, LLC$453
- Dexcom, Inc.$409
- Sanofi-aventis U.S. LLC$384
- AbbVie$360
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,57796%
- Education$1834%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 62 | $1,137 |
| Amgen(2 entities) | 36 | $637 |
| Lilly USA, LLC | 27 | $453 |
| Dexcom, Inc. | 19 | $409 |
| Sanofi-aventis U.S. LLC | 17 | $384 |
| AbbVie | 17 | $360 |
| IBSA Pharma Inc. | 22 | $356 |
| Abbott | 16 | $286 |
| Bayer | 13 | $204 |
| Ascendis Pharma Endocrinology Inc | 5 | $86 |
| Xeris Pharmaceuticals, Inc. | 4 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $55 |
| Shire North American Group Inc | 3 | $54 |
| Boehringer Ingelheim | 3 | $53 |
| AstraZeneca | 2 | $43 |
| Tandem Diabetes Care, Inc. | 1 | $36 |
| Medtronic | 2 | $30 |
| Roche Diabetes Care, Inc. | 2 | $26 |
| GRT US Holding, Inc. | 1 | $22 |
| Lifescan, Inc. | 2 | $20 |
| Novartis | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,760 in reported general payments places this provider in the 75th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $77,928 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $57,880 |
| SynthroidLevothyroxine Sodium | 532 | $52,723 |
| JardianceEmpagliflozin | 24 | $47,917 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $34,459 |
| TrulicityDulaglutide | 19 | $21,908 |
| TirosintLevothyroxine Sodium | 31 | $13,097 |
| Humalog Kwikpen U-100Insulin Lispro | 39 | $12,643 |
| RybelsusSemaglutide | 12 | $11,434 |
| Novolog FlexpenInsulin Aspart | 17 | $7,361 |
| HumalogInsulin Lispro | 17 | $2,866 |
| Atorvastatin Calcium | 209 | $2,592 |
| LantusInsulin Glargine,hum.Rec.Anlog | 21 | $2,528 |
| Levothyroxine Sodium | 179 | $2,114 |
| Ezetimibe | 72 | $1,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,137 | $89,36267 claims |
| AbbVieSynthroid | $360 | $52,723532 claims |
| Boehringer IngelheimJardiance | $53 | $47,91724 claims |
| Lilly USA, LLCTrulicity, Humalog | $453 | $24,77436 claims |
| IBSA Pharma Inc.Tirosint | $356 | $13,09731 claims |
| Sanofi-aventis U.S. LLCLantus | $384 | $2,52821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
Other endocrinology, diabetes & metabolism in Portland
- Michael McClungPortland$1.3M
- Maria FleseriuPortland$464K
- James NeifingPortland$311K
- Rodica BusuiPortland$255K
- Jonathan PurnellPortland$212K
- Eric OrwollPortland$94K
- Paul DuellPortland$91K
- Sergio FazioPortland$88K
- Nancy CuroshPortland$59K
- Andrew AhmannPortland$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.